National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment

Blood

Volumn 87, Issue 12, 1996, Pages 4990-4997

  Cheson, Bruce D ^a   Bennett, John M ^a   Grever, Michael ^a   Kay, Neil ^a   Keating, Michael J ^a   O'Brien, Susan ^a   Rai, Kanti R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; FLUDARABINE; HEMOGLOBIN;

B CELL LEUKEMIA; BLOOD TOXICITY; BONE MARROW EXAMINATION; CANCER STAGING; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOPHENOTYPING; INFECTIOUS COMPLICATION; LEUKEMIA REMISSION; LIVER TOXICITY; LUNG TOXICITY; LYMPHOCYTE COUNT; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT INDICATION;

EID: 0029981025     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.12.4990.bloodjournal87124990     Document Type: Review

References (38)

1. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, Foon KA: Guidelines for clinical protocols for chronic lymphocytic leukemia: Report of the NCI-sponsored Working Group. Amer J Hematol 29:152, 1988
2. International Workshop on Chronic Lymphocytic Leukemia: Chronic lymphocytic leukemia: Recommendations for diagnosis, staging, and response criteria. Ann Intern Med 110:236, 1989
3. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Valasquez W, Plunkett W, Freireich EJ, McCredie KB: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19, 1989
4. Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB: Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9:44, 1991
5. Hiddemann W, Rottmann R, Wormann B, Thiel A, Essink M, Ottensmeier C, Freund M, Büchner T, van de Loo J: Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study. Ann Hematol 63:1, 1991
6. Whelan JS, Davis CL, Rule S, Ranson M, Smith OP, Mehta AB, Catovsky D, Rohatiner AZS, Lister TA: Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 64:120, 1991
7. Sorensen JM, Vena D, Fallavollita A, Cheson BD: Treatment of refractory chronic lymphocytic leukemia (CLL) with fludarabine monophosphate (FAMP). Proc Am Soc Clin Oncol 11:264, 1992 (abstr 867)
8. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81:2878, 1993
9. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82:1695, 1993
10. Melo JV, Catovsky D, Galton DAG: The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 63:377, 1986
11. Catovsky D: Diagnosis and treatment of CLL variants, in Cheson BD (ed): Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments. New York, NY, Dekker, 1993, p 369
12. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Harmelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
13. French Cooperative Group on Chronic Lymphocytic Leukaemia: Natural history of stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol 76:45, 1990
14. Molica S: Progression and survival studies in early chronic lymphocytic leukemia. Blood 78:895, 1991
15. Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J Clin Pathol 42:567, 1989
16. Reinisch W, Willheim M, Hilgarth M, Gasche C, Mader R, Szepfalusi S, Steger G, Berger R, Lechner K, Boltz-Nitulescu G, Schwarzmeier JD: Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol 12:2146, 1994
17. Hoyer JD, Ross CW, Li C-Y, Witzig TE, Gascoyne RD, Dewald GW, Hanson CA: True T-cell chronic lymphocytic leukemia: A morphologic and immunophenotypic study of 25 cases. Blood 86:1163, 1995
18. Rozman C, Montserrat E, Rodríguez-Fernández JM, Ayats R, Vallespí T, Parody R, Ríos A, Prados D, Morey M, Gomis F, Alcalá A, Gutiérrez M, Maldonado J, Gonzalez C, Giralt M, Hernández-Nieto L, Cabrera A, Fernández-Rañada JM: Bone marrow histologic pattern - The best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases. Blood 64:642, 1984
19. Escudier SM, Pereira-Leahy JM, Drach JW, Weier HU, Goodacre AM, Cork MA, Trujillo JM, Keating MJ, Andreef M: Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood 81:2702, 1993
20. Bentz M, Huck K, du Manoir S, Joos S, Werner CA, Fischer K, Döhner H, Lichter P: Comparative genomic hybridization in chronic B-cell leukemias shows a high incidence of chromosomal gains and losses. Blood 85:3610, 1995
21. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC: bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82:1820, 1993
22. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW: p53 Gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452, 1993
23. Döhner H, Fischer K, Mentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580, 1995
24. Stilgenbauer S, Döhner H, Bulgay-Morschel M, Weitz S, Bentz M, Lichter P: High frequency of monoallelic retinoblastoma gene deletion in B-cell chronic lymphoid leukemia shown by interphase cytogenetics. Blood 81:2118, 1993
25. Brown AG, Ross FM, Dunne EM, Steel M, Weir-Thompson EM: Evidence for a new tumor suppressor locus (DBM) in human B-cell neoplasia telomeric to the retinoblastoma gene. Nature Gen 3:67, 1993
26. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS: Clinical staging of chronic lymphocytic leukemia. Blood 46:219, 1975
27. Binet JL, Leporrier M, Dighiero G, Charron D, D'Athis P, Vaughier G, Beral HM, Natall JC, Raphael M, Nizet B, Follezou JY: A clinical staging system for chronic lymphocytic leukemia. Prognostic significance. Cancer 40:855, 1977
28. Rai KR: A critical analysis of staging in CLL, in Gale RP, Rai KR (eds): Chronic Lymphocytic Leukemia. Recent Progress and Future Direction. New York, NY, Liss, 1987, p 253
29. Cheson B: Immunologic and immunosuppressive complications of purine analogue therapy. J Clin Oncol 13:2431, 1995
30. French Cooperative Group on Chronic Lymphocytic Leukemia: A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood 75:1422, 1990
31. Shustik C, Mick R, Silver R, Sawitsky A, Rai K, Shapiro L: Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation. Hematol Oncol 6:7, 1988
32. Rabinowe SN, Soiffer RJ, Gribben JG, Daley H, Freedman AS, Daley J, Pesek K, Neuberg D, Pinkus G, Leavitt PR, Spector NA, Grossbard ML, Anderson K, Robertson MJ, Mauch P, Chayt-Marcus K, Ritz J, Nadler LM: Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 82:1366, 1993
33. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, van Besien KW, Mehra RC, Giralt SA, Ippoliti C, Marshall M, Thomas MW, O'Brien S, Robertson LE, Deisseroth AB, Champlin RE: Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results. J Clin Oncol 12:748, 1994
34. Michallet M, Archimbaud E, Bandini G, Rowlings P, Deeg HJ, Gahrton G, Montserrat E, Rozman C, Gratwohl A, Gale RP: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 124:311, 1996
35. Robertson LE, Huh YO, Butler JJ, Pugh WC, Hirsch-Ginsberg C, Stass S, Kantarjian H, Keating MJ: Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: Clinical, pathologic, immunophenotypic, and molecular analysis. Blood 80:29, 1992
36. Juliusson G, Liliemark J: High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease in blood lymphocyte count. J Clin Oncol 11:679, 1993
37. Keating MJ, Lerner S, Kantarjian H, Freireich EJ, O'Brien S: The serum beta2-microglobulin (beta2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). Blood 86:606a, 1995 (abstr, suppl 1)
38. Wittes RE (ed): Manual of Oncologic Therapeutics: 1991/ 1992. Philadelphia, PA, Lippincott, 1991, p 446